GARNELLE FLOREZ: Open Payments
NPI 1912675307 · KEARNEY, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,373 in 60 payments from 10 companies in 2025. Trend: 2023 $137 · 2024 $212 · 2025 $1,373
Food & beverage: $1,262Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $426 |
| Otsuka America Pharmaceutical, Inc. | 10 | $270 |
| Alkermes, Inc. | 9 | $213 |
| Teva Pharmaceuticals USA, Inc. | 5 | $172 |
| Axsome Therapeutics, Inc. | 1 | $76 |
| Janssen Pharmaceuticals, Inc | 4 | $74 |
| Neurocrine BioSciences, Inc. | 1 | $65 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $29 |
| Lundbeck LLC | 1 | $19 |
Products named: VRAYLAR, ARISTADA, REXULTI, ABILIFY ASIMTUFII, Auvelity, INGREZZA, UZEDY, SPRAVATO.
Industry payments across NE — which companies pay providers there.
